COVID-19 is a widespread respiratory disease. At our company, we are committed to developing state-of-the-art IVD reagents/kits and diagnostic equipment to tackle the challenges in COVID-19 diagnosis. As your trusted partner in COVID-19 diagnostic research, we offer comprehensive solutions to meet all your scientific research needs effectively.
Introduction to COVID-19
COVID-19, triggered by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has surfaced as a worldwide health emergency. The primary mode of SARS-CoV-2 transmission is through respiratory droplets released when infected individuals breathe, cough, talk, or sneeze. This virus predominantly affects the respiratory system by attaching to ACE2 receptors in the lungs, instigating inflammation that can result in pneumonia and severe respiratory complications.
Fig. 1 Pathophysiology of SARS-CoV-2 infection. (Zhu Y, et al., 2023)
IVD Development for COVID-19
The development of in vitro diagnostic (IVD) tools for COVID-19 has been pivotal in the global response to the pandemic. These diagnostic tests are pivotal in swiftly and precisely detecting the SARS-CoV-2 virus, facilitating effective disease control, transmission containment, and the enforcement of public health protocols.
Viral RNA Detection
PCR tests are considered the gold standard for COVID-19 diagnosis, detecting viral RNA in respiratory samples. Viral RNA amplification is employed to validate the diagnosis. PCR tests are highly sensitive and specific, providing reliable results for confirming active infections.
Antigen Testing
Antigen tests detect specific proteins on the surface of the SARS-CoV-2 virus, such as the nucleocapsid protein (N protein) and the spike protein (S protein). These tests are rapid and cost-effective, providing swift results that are suitable for point-of-care settings.
Antibody Testing
Antibody tests detect the presence of antibodies produced by the immune system in response to SARS-CoV-2 infection. These tests can aid in identifying previous exposure to the virus and evaluating immune response but are not appropriate for early detection of active infections.
IVD Kits for COVID-19
In vitro diagnostic (IVD) kits play a critical role in identifying SARS-CoV-2. Early and accurate diagnosis is critical to implementing appropriate therapeutics and public health interventions to curb the spread of the virus.
| Kits |
Applications |
Detection Methods |
| COVID-19 Nucleic Acid Detection Kit |
Detection of SARS-CoV-2 viral RNA in samples qualitatively. |
RT-PCR |
| COVID-19 Antigen Detection Kit |
Identification of SARS-CoV-2 nucleocapsid protein (NP). |
Lateral Flow Test |
| SARS-CoV-2 IgM/IgG Detection Kit |
Qualitative assessment of IgM and IgG antibodies against the nucleocapsid protein (NP) of the SARS-CoV-2 virus in blood samples. |
Lateral Flow Immunoassay |
| COVID-19 Rapid Test Kit |
These kits offer rapid results and are commonly utilized for mass testing initiatives and screening across diverse settings. |
Immunoassay |
Our Services
Our company is dedicated to pioneering advancements in IVD solutions tailored for combating COVID-19. With a primary focus on the development of innovative test kits targeting SARS-CoV-2 viral RNA, antigens, and anti-SARS-CoV-2 antibodies, our mission is to facilitate precise and reliable identification of SARS-CoV-2 viral infections. By specializing in the creation of point-of-care testing (POCT) kits, we aim to provide convenient and rapid diagnostic tools for timely intervention and effective management of this infectious disease.
IVD Product Development Services
We specialize in creating innovative diagnostic devices tailored for COVID-19 testing. These devices are designed for ease of use, rapid results, and high accuracy, enhancing the efficiency of testing processes. Our companion diagnostic development services aim to enhance personalized therapeutic approaches for COVID-19 by identifying biomarkers that help predict individual responses to specific therapies.
If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Zhu Y, Sharma L, Chang D. Pathophysiology and clinical management of coronavirus disease (COVID-19): a mini-review[J]. Frontiers in Immunology, 2023, 14: 1116131.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
